Streptokinase and urokinase have proved to be useful in a limited number of clinical conditions. Mainly because of the risk and unpredictability of bleeding with this first generation of thrombolytic agents, thrombolysis has not been ingrained in medical practice. In the interim, more fibrin-specific thrombolytic agents have been developed such as acylated streptokinase-human plasminogen comple...

Streptokinase is a potent fibrinolytic agent which is widely used in treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and acute myocardial infarction (MI). Major limitation of this enzyme is its short biological half-life in the blood stream. Our previous report showed that complexing streptokinase with chitosan could be a solution to overcome this limitation. The aim of this re...

Acute Coronary Syndromes TIMI 14 (Final Results) Presenter: Elliott Antman, MD, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass. The study: A prospective, multicenter, randomized, controlled trial of combined therapy with thrombolytic agents and the platelet glycoprotein IIb/IIIa antagonist abciximab in patients with AMI. A total of 681 patients were randomized to standard...

OBJECTIVE To assess the usefulness of heparin, alteplase, and streptokinase in removing blood stains. DESIGN Randomised controlled trial. SETTING Hospital laundry. INTERVENTIONS Blood stains were allocated to treatment with alteplase, streptokinase, heparin, a commercial enzymatic stain remover, or no treatment at all after three or seven hours and then washed in hot or cold water two hou...

The activity of alpha-hydroxybutyrate dehydrogenase, creatine kinase, creatine kinase MB and aspartate aminotransferase was measured on serial plasma samples from patients with acute myocardial infarction. The study was part of a multicentre randomised trial of the effect of thrombolytic treatment in the acute phase of acute myocardial infarction. The applicability and comparability of enzyme t...

Guillain-Barre syndrome (GBS) is an eponym for a heterogeneous group of immune-mediated peripheral neuropathies. We describe a case of GBS in a patient who recieved intravenous streptokinase therapy for acute anterior myocardial infarction. Clinical symptoms are thought to result from streptokinase-antibody complex mediated damage to the local blood-nerve barrier. Patient was treated with 5-day...

' Reid HA, Nkrumah FK. Fibrin degradation products in cerebral malaria. Lancet 1972;i:218-21. 2 Jaroonkesama N. Intravascular coagulation in falciparum malaria. Lancet 1972;i :221-3. 3Preston FE, Edwards IR. The successful use of streptokinase in a patient with purpura fulminans. Br MedJ 1973;iii :329-30. 4 Martindale W. Streptokinase. Extra Pharmacopoeia, 27th ed. London: Pharmaceutical Press,...

Streptokinase is a fibrinolytic agent that enhances plasmin activation and is used in selected patients with acute ST elevation myocardial infarction (STEMI). Similar to the other thrombolytics, a common side effect is bleeding, especially from venous puncture sites. Here, we present a case of acute anterior wall STEMI complicated by large spontaneous iliopsoas hematoma after streptokinase admi...

17 ± 2.7 1.9 ± 0.4 5.9 ± 0.7 89 ± 28 Van Acker et al. (1) reported the presence of macro-LDH in serum 10 days after administration of streptokinase in the very acute phase of an acute myocardial infarction (AM!). They claimed a causal relationship between the finding of macro-LDH and administered streptokinase. However, a relationship with AM! itself, or its underlying cause, is not to be exclu...